Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC.AGIO · Entity 4499 | Director | December 31, 2022 | February 03, 2023 |
| ALNYLAM PHARMACEUTICALS, INC.ALNY · Entity 3132 | Director · Chief Executive Officer | December 21, 2021 | December 23, 2021 |
| Beam Therapeutics Inc.BEAM · Entity 4227 | Director | June 03, 2026 | June 05, 2026 |
| Hemab Therapeutics Holdings, Inc.COAG · Entity 4476 | Director | January 29, 2026 | May 04, 2026 |
| Kymera Therapeutics, Inc.KYMR · Entity 3545 | Director | June 24, 2026 | June 25, 2026 |
| PROKIDNEY CORP.PROK · Entity 5181 | Director | June 29, 2023 | July 03, 2023 |
| Rapport Therapeutics, Inc.RAPP · Entity 4394 | Director | June 10, 2026 | June 10, 2026 |
| TAKEDA PHARMACEUTICAL CO LTDTAK · Entity 2662 | Director | July 01, 2026 | July 06, 2026 |
| bluebird bio, Inc.BLUE · Entity 78923 | Director | September 14, 2017 | September 18, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AGIOS PHARMACEUTICALS, INC.
Report date December 31, 2022 · Filed February 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | Direct | 28,528 |
Reported balance
After 2022-09-20 transaction · row 1
1 source rowRow 1 · 2022-09-20 · Gift · Disposed 1,500 · Balance 28,528 F1: This disposition reflects a bona fide gift of 1,500 shares to charity. |
Filing footnotes · ownership attribution and instrument terms
F1: This disposition reflects a bona fide gift of 1,500 shares to charity.
ALNYLAM PHARMACEUTICALS, INC.
Report date December 21, 2021 · Filed December 23, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 227,663 |
Ending reported balance
After 2021-12-22 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2021-12-21 · Grant · Acquired 14,167 · Balance 234,299 F1: On February 28, 2019, the reporting person was granted performance-based restricted stock units (PSU) in connection with the 2018 year-end compensation review. One third of the PSU award vests upon the achievement of each of three specific clinical development, regulatory or commercial events. The People, Culture and Compensation Committee of the Board determined that the final performance criterion was met and the final one-third of the PSU award vested as of December 21, 2021. Row 2 · 2021-12-22 · Tax withholding · Disposed 6,315 · Balance 227,984 F2: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the PSU award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event. Row 3 · 2021-12-22 · Tax withholding · Disposed 2 · Balance 227,982 F2: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the PSU award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event. Row 4 · 2021-12-22 · Tax withholding · Disposed 319 · Balance 227,663 F2: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the PSU award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event. |
| Common StockSEC Table I · non-derivative | Indirectby Managed Account | 3,133 |
Reported balance
Holding disclosure · report date 2021-12-21 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 3,133 F3: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. |
Filing footnotes · ownership attribution and instrument terms
F1: On February 28, 2019, the reporting person was granted performance-based restricted stock units (PSU) in connection with the 2018 year-end compensation review. One third of the PSU award vests upon the achievement of each of three specific clinical development, regulatory or commercial events. The People, Culture and Compensation Committee of the Board determined that the final performance criterion was met and the final one-third of the PSU award vested as of December 21, 2021.
F2: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the PSU award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event.
F3: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.
Beam Therapeutics Inc.
Report date June 03, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.55 · Expires 2036-06-03 | Direct | 19,676 |
Reported balance
After 2026-06-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 19,676 · Balance 19,676 F1: The option vests in full on the earlier of the first anniversary of the date of grant and immediately prior to the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in full on the earlier of the first anniversary of the date of grant and immediately prior to the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date.
Hemab Therapeutics Holdings, Inc.
Report date January 29, 2026 · Filed May 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 35,948 |
Ending reported balance
After 2026-05-04 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-05-04 · Conversion · Acquired 17,974 · Balance 17,974 F1: The warrant was granted on January 29, 2026. The shares underlying the warrant vest over three years in equal monthly installments from January 1, 2026 through January 1, 2029. Row 2 · 2026-05-04 · Conversion · Acquired 17,974 · Balance 35,948 F1: The warrant was granted on January 29, 2026. The shares underlying the warrant vest over three years in equal monthly installments from January 1, 2026 through January 1, 2029. |
| Warrants (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.00 · Expires 2036-01-28 | Direct | 107,338 |
Reported balance
After 2026-01-29 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-01-29 · Grant · Acquired 107,338 · Balance 107,338 F1: The warrant was granted on January 29, 2026. The shares underlying the warrant vest over three years in equal monthly installments from January 1, 2026 through January 1, 2029. |
| Series B Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-05-04 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-04 · Conversion · Disposed 817 · Balance 0 F1: The warrant was granted on January 29, 2026. The shares underlying the warrant vest over three years in equal monthly installments from January 1, 2026 through January 1, 2029. F2: Each share of Series B Preferred Stock and Series C Preferred Stock converted into 22 shares of common stock without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. |
| Series C Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-05-04 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-05-04 · Conversion · Disposed 817 · Balance 0 F1: The warrant was granted on January 29, 2026. The shares underlying the warrant vest over three years in equal monthly installments from January 1, 2026 through January 1, 2029. F2: Each share of Series B Preferred Stock and Series C Preferred Stock converted into 22 shares of common stock without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: The warrant was granted on January 29, 2026. The shares underlying the warrant vest over three years in equal monthly installments from January 1, 2026 through January 1, 2029.
F2: Each share of Series B Preferred Stock and Series C Preferred Stock converted into 22 shares of common stock without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
Kymera Therapeutics, Inc.
Report date June 24, 2026 · Filed June 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $99.87 · Expires 2036-06-23 | Direct | 6,068 |
Reported balance
After 2026-06-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-24 · Grant · Acquired 6,068 · Balance 6,068 F1: The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 24, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 24, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders.
PROKIDNEY CORP.
Report date June 29, 2023 · Filed July 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.56 · Expires 2033-06-29 | Direct | 48,128 |
Reported balance
After 2023-06-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-29 · Grant · Acquired 48,128 · Balance 48,128 F1: These options were granted under the Issuer's non-employee director compensation policy. F2: The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: These options were granted under the Issuer's non-employee director compensation policy.
F2: The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting.
Rapport Therapeutics, Inc.
Report date June 10, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.21 · Expires 2036-06-10 | Direct | 15,200 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 15,200 · Balance 15,200 F1: The shares underlying this option shall vest upon the earlier of (i) June 10, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option shall vest upon the earlier of (i) June 10, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.
TAKEDA PHARMACEUTICAL CO LTD
Report date July 01, 2026 · Filed July 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 10,400 |
Reported balance
After 2026-07-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-07-01 · Grant · Acquired 3,800 · Balance 10,400 F1: Represents an award of restricted stock units (RSU). Each RSU represents a contingent right to receive one Ordinary Share, which will be converted into an equivalent number of American Depositary Shares following vest. The RSUs vest on June 1, 2029. F2: Reflects the conversion of 3,100 Ordinary Shares into 6,200 American Depositary Shares upon vesting of RSUs. |
| Tax Obligation AwardSEC Table II · derivative / convertible security · Expires 2026-06-01 | Direct | 0 |
Reported balance
After 2026-07-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-07-10 · Disposition to issuer · Disposed 1,152 · Balance 0 F3: Each Tax Obligation Award was the economic equivalent of one Ordinary Share that, upon vest, was converted into to a cash payment primarily to cover tax obligations. Any remaining proceeds from the disposition of the associated Ordinary Shares will be delivered to the reporting person on July 10. F4: The price reported in Column 8 is a weighted average price denominated in Yen. These shares were sold in transactions at prices ranging from JPY 4,883 to JPY 5,045, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
| Tax Obligation AwardSEC Table II · derivative / convertible security · Expires 2029-06-01 | Direct | 1,319 |
Reported balance
After 2026-07-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-07-01 · Grant · Acquired 1,319 · Balance 1,319 F5: Each Tax Obligation Award is the economic equivalent of one Ordinary Share that, upon vest, will be converted to a cash payment primarily to cover tax obligations at the then-current market price of the Ordinary Shares. |
| American Depositary SharesSEC Table I · non-derivative | Direct | 13,800 |
Reported balance
Holding disclosure · report date 2026-07-01 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 13,800 F2: Reflects the conversion of 3,100 Ordinary Shares into 6,200 American Depositary Shares upon vesting of RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of restricted stock units (RSU). Each RSU represents a contingent right to receive one Ordinary Share, which will be converted into an equivalent number of American Depositary Shares following vest. The RSUs vest on June 1, 2029.
F2: Reflects the conversion of 3,100 Ordinary Shares into 6,200 American Depositary Shares upon vesting of RSUs.
F3: Each Tax Obligation Award was the economic equivalent of one Ordinary Share that, upon vest, was converted into to a cash payment primarily to cover tax obligations. Any remaining proceeds from the disposition of the associated Ordinary Shares will be delivered to the reporting person on July 10.
F4: The price reported in Column 8 is a weighted average price denominated in Yen. These shares were sold in transactions at prices ranging from JPY 4,883 to JPY 5,045, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F5: Each Tax Obligation Award is the economic equivalent of one Ordinary Share that, upon vest, will be converted to a cash payment primarily to cover tax obligations at the then-current market price of the Ordinary Shares.
bluebird bio, Inc.
Report date September 14, 2017 · Filed September 18, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,843 |
Ending reported balance
After 2017-09-14 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2017-09-14 · Exercise / conversion · Acquired 18,868 · Balance 24,711 Row 2 · 2017-09-14 · Sale · Disposed 18,268 · Balance 6,443 F1: The range in prices for the transaction reported on this line was $130.80 to $131.75. The average weighted price was $131.1935. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Row 3 · 2017-09-14 · Sale · Disposed 600 · Balance 5,843 F2: The range in prices for the transaction reported on this line was $131.80 to $131.90. The average weighted price was $131.8167. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.09 · Expires 2022-01-08 | Direct | 0 |
Reported balance
After 2017-09-14 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-09-14 · Exercise / conversion · Acquired 18,868 · Balance 0 F3: This option vests in 48 equal monthly installments, commencing on April 1, 2011. |
Filing footnotes · ownership attribution and instrument terms
F1: The range in prices for the transaction reported on this line was $130.80 to $131.75. The average weighted price was $131.1935. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F2: The range in prices for the transaction reported on this line was $131.80 to $131.90. The average weighted price was $131.8167. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3: This option vests in 48 equal monthly installments, commencing on April 1, 2011.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 27, 2018 Filed Sep 28, 2018 20:56 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantPerformance Stock Option 2015 (right to buy) · Derivative | 16,250 | $0.00 Strike: $88.95 | $0.00 |
DisclosureSEC source: 0001735276-18-000073 · edgardoc.xml · derivative · entry 1 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,750 Underlying: Common Stock · 16,250 shares Expires 2025-12-18 F1 · kind: On December 18, 2015, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option will vest upon the achievement of each of four specific clinical development and regulatory events, as approved by our compensation committee. Effective September 27, 2018, the compensation committee of the Company determined the third performance criterion had been met and the option vested as to one-quarter of the shares. Read SEC document |
| September 12, 2018 Filed Sep 13, 2018 20:01 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 14,162 | $71.74 | $1,015,981.88 |
DisclosureSEC source: 0001209191-18-050824 · doc4.xml · nonDerivative · entry 3 MARAGANORE JOHN · CIK 0001180432 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,047 F3 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $71.70 to $72.17. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| September 12, 2018 Filed Nov 6, 2018 21:12 UTC Amendment | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 0 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-057372 · doc4a.xml · nonDerivative · entry 1 MARAGANORE JOHN · CIK 0001180432 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,209 F1 · kind: On September 13, 2018, the reporting person filed a Form 4 reporting the sale of 14,162 shares of common stock. The previously reported transaction was subsequently broken and unwound by the broker and, therefore, did not in fact occur for the reporting person's account. As of September 12, 2018, the reporting person beneficially owned 36,209 shares of common stock of Agios Pharmaceuticals, Inc. F1 · price: On September 13, 2018, the reporting person filed a Form 4 reporting the sale of 14,162 shares of common stock. The previously reported transaction was subsequently broken and unwound by the broker and, therefore, did not in fact occur for the reporting person's account. As of September 12, 2018, the reporting person beneficially owned 36,209 shares of common stock of Agios Pharmaceuticals, Inc. Read SEC document |
| September 11, 2018 Filed Sep 13, 2018 20:01 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 2,400 | $73.82 | $177,168.00 |
DisclosureSEC source: 0001209191-18-050824 · doc4.xml · nonDerivative · entry 2 MARAGANORE JOHN · CIK 0001180432 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,209 F2 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $73.33 to $74.25. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| September 11, 2018 Filed Sep 13, 2018 20:01 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 11,155 | $72.52 | $808,960.60 |
DisclosureSEC source: 0001209191-18-050824 · doc4.xml · nonDerivative · entry 1 MARAGANORE JOHN · CIK 0001180432 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,609 F1 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $72.27 to $72.89. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| August 21, 2018 Filed Aug 23, 2018 20:15 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantPerformance Stock Option 2015 (right to buy) · Derivative | 16,250 | $0.00 Strike: $88.95 | $0.00 |
DisclosureSEC source: 0001735276-18-000062 · edgardoc.xml · derivative · entry 1 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,500 Underlying: Common Stock · 16,250 shares Expires 2025-12-18 F1 · kind: On December 18, 2015, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option will vest upon the achievement of each of four specific clinical development or commercial events, as approved by our compensation committee. Effective August 21, 2018, the compensation committee of the Company determined the second performance criterion had been met and the option vested as to one-quarter of the shares. Read SEC document |
| August 10, 2018 Filed Aug 14, 2018 22:33 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantPerformance Based Stock Option 2014 (right to buy) · Derivative | 25,000 | $0.00 Strike: $96.45 | $0.00 |
DisclosureSEC source: 0001325812-18-000029 · primary_doc.xml · derivative · entry 2 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 25,000 shares Expires 2024-12-17 F2 · kind: On December 17, 2014, the reporting person was granted a performance based stock option to purchase shares of ALNY Common Stock. One-third of the shares subject to the option will vest upon the achievement of each of three specific clinical development and regulatory events, as approved by our compensation committee. Effective August 10, 2018, the compensation committee of the Company determined the final performance criteria had been met and the option vested as to the final third of the award. Read SEC document |
| August 10, 2018 Filed Aug 14, 2018 22:33 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantPerformance Based Stock Option 2013 (right to buy) · Derivative | 25,000 | $0.00 Strike: $63.00 | $0.00 |
DisclosureSEC source: 0001325812-18-000029 · primary_doc.xml · derivative · entry 1 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 15,000 shares Expires 2023-12-18 F1 · kind: On December 18, 2013, the reporting person was granted a performance based stock option to purchase shares of ALNY Common Stock. One-third of the shares subject to the option will vest upon the achievement of each of three specific clinical development and regulatory events, as approved by our compensation committee. Effective August 10, 2018, the compensation committee of the Company determined the final performance criteria had been met and the option will vest as to the final third of the award. Read SEC document |
| July 25, 2018 Filed Jul 27, 2018 20:07 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $21.35 | $0.00 |
DisclosureSEC source: 0001735276-18-000039 · edgardoc.xml · derivative · entry 9 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,636 Underlying: Common Stock · 50,000 shares Expires 2018-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 16, 2018. The 50,000 options exercised and sold by the reporting person were due to expire on December 8, 2018. F8 · derivative.exercise_date: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| July 25, 2018 Filed Jul 27, 2018 20:07 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 1,400 | $106.25 | $148,750.00 |
DisclosureSEC source: 0001735276-18-000039 · edgardoc.xml · nonDerivative · entry 6 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,297 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 16, 2018. The 50,000 options exercised and sold by the reporting person were due to expire on December 8, 2018. F6 · price: Sale prices ranged from $106.18 to $106.33. Read SEC document |
| July 25, 2018 Filed Jul 27, 2018 20:07 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 34,995 | $105.83 | $3,703,520.85 |
DisclosureSEC source: 0001735276-18-000039 · edgardoc.xml · nonDerivative · entry 5 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,697 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 16, 2018. The 50,000 options exercised and sold by the reporting person were due to expire on December 8, 2018. F5 · price: Sale prices ranged from $105.17 to $106.13. Read SEC document |
| July 25, 2018 Filed Jul 27, 2018 20:07 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 7,758 | $104.83 | $813,271.14 |
DisclosureSEC source: 0001735276-18-000039 · edgardoc.xml · nonDerivative · entry 4 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,692 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 16, 2018. The 50,000 options exercised and sold by the reporting person were due to expire on December 8, 2018. F4 · price: Sale prices ranged from $104.17 to $105.15. Read SEC document |
| July 25, 2018 Filed Jul 27, 2018 20:07 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 3,847 | $103.69 | $398,895.43 |
DisclosureSEC source: 0001735276-18-000039 · edgardoc.xml · nonDerivative · entry 3 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,450 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 16, 2018. The 50,000 options exercised and sold by the reporting person were due to expire on December 8, 2018. F3 · price: Sale prices ranged from $103.10 to $104.04. Read SEC document |
| July 25, 2018 Filed Jul 27, 2018 20:07 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 2,000 | $102.51 | $205,020.00 |
DisclosureSEC source: 0001735276-18-000039 · edgardoc.xml · nonDerivative · entry 2 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,297 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 16, 2018. The 50,000 options exercised and sold by the reporting person were due to expire on December 8, 2018. F2 · price: Sale prices ranged from $101.99 to $102.94. Read SEC document |
| July 25, 2018 Filed Jul 27, 2018 20:07 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 50,000 | $21.35 | $1,067,500.00 |
DisclosureSEC source: 0001735276-18-000039 · edgardoc.xml · nonDerivative · entry 1 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,297 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 16, 2018. The 50,000 options exercised and sold by the reporting person were due to expire on December 8, 2018. Read SEC document |
| July 10, 2018 Filed Jul 27, 2018 20:07 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | OtherCommon Stock | 31 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-18-000039 · edgardoc.xml · nonDerivative · entry 8 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Managed Account Disclosed balance after: 3,021 F7 · kind: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F7 · price: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F7 · ownership.nature: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. Read SEC document |
| May 31, 2018 Filed Jun 4, 2018 20:26 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 1,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-035082 · doc4.xml · derivative · entry 2 MARAGANORE JOHN · CIK 0001180432 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,400 Underlying: Common stock · 1,400 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on May 31, 2018. The shares underlying the stock units will vest in full on May 31, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F3 · derivative.expiration_date: The restricted stock units were granted on May 31, 2018. The shares underlying the stock units will vest in full on May 31, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| May 31, 2018 Filed Jun 4, 2018 20:26 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock option (right to buy) · Derivative | 5,700 | $0.00 Strike: $93.50 | $0.00 |
DisclosureSEC source: 0001209191-18-035082 · doc4.xml · derivative · entry 1 MARAGANORE JOHN · CIK 0001180432 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,700 Underlying: Common stock · 5,700 shares Expires 2028-05-30 F1 · derivative.exercise_date: This option was granted on May 31, 2018. The shares underlying this option vest as to 100% of the underlying shares on May 31, 2019. Read SEC document |
| April 16, 2018 Filed Jul 27, 2018 20:07 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | OtherCommon Stock | 30 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-18-000039 · edgardoc.xml · nonDerivative · entry 7 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Managed Account Disclosed balance after: 2,990 F7 · kind: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F7 · price: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F7 · ownership.nature: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 22:49 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 52,500 | $0.00 Strike: $119.13 | $0.00 |
DisclosureSEC source: 0001553878-18-000012 · edgardoc.xml · derivative · entry 1 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,500 Underlying: Common Stock · 52,500 shares Expires 2028-02-28 F1 · shares: Represents the time-vested portion of the reporting person's Annual Stock Option Award for 2017. The reporting person also received 52,500 options to purchase shares of ALNY common stock that will vest upon the achievement of three specific performance conditions, which will be reported on a Form 4 if and when each performance condition is met and the option vests. F2 · derivative.exercise_date: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to the remaining shares ratably at the end of each three-month period thereafter over the following thirty-three (33) months Read SEC document |
| December 20, 2017 Filed Dec 21, 2017 21:36 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantPerformance Based Stock Option 2016 (right to buy) · Derivative | 6,250 | $0.00 Strike: $42.22 | $0.00 |
DisclosureSEC source: 0001325812-17-000035 · primary_doc.xml · derivative · entry 3 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,250 Underlying: Common Stock · 6,250 shares Expires 2026-12-20 F2 · kind: On December 20, 2016, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option will vest upon the achievement of each of four specific clinical development, regulatory or commercial events, as approved by our compensation committee. Effective December 20, 2017, the compensation committee of the Company determined the first performance criterion had been met and the option vested as to one-quarter of the shares. Read SEC document |
| December 19, 2017 Filed Dec 21, 2017 21:36 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 1,587 | $0.00 Strike: $63.00 | $0.00 |
DisclosureSEC source: 0001325812-17-000035 · primary_doc.xml · derivative · entry 4 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,413 Underlying: Common Stock · 1,587 shares Expires 2023-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter Read SEC document |
| December 19, 2017 Filed Dec 21, 2017 21:36 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 1,587 | $63.00 | $99,981.00 |
DisclosureSEC source: 0001325812-17-000035 · primary_doc.xml · nonDerivative · entry 1 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,297 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 22, 2017 Filed Nov 24, 2017 23:55 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (Right to Buy) · Derivative | 73,415 | $0.00 Strike: $31.39 | $0.00 |
DisclosureSEC source: 0001553878-17-000069 · primary_doc.xml · derivative · entry 7 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 73,415 shares Expires 2017-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 13, 2017. The 73,415 options exercised and sold by the reporting person were due to expire on December 12, 2017. F7 · derivative.exercise_date: The stock option vested as to 25% of the shares on the first anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. F1 · derivative.expiration_date: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 13, 2017. The 73,415 options exercised and sold by the reporting person were due to expire on December 12, 2017. Read SEC document |
| November 22, 2017 Filed Nov 24, 2017 23:55 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 2,683 | $132.73 | $356,114.59 |
DisclosureSEC source: 0001553878-17-000069 · primary_doc.xml · nonDerivative · entry 5 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,710 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 13, 2017. The 73,415 options exercised and sold by the reporting person were due to expire on December 12, 2017. F5 · price: Sale prices ranged from $132.38 to $133.34. Read SEC document |
| November 22, 2017 Filed Nov 24, 2017 23:55 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 20,433 | $131.82 | $2,693,478.06 |
DisclosureSEC source: 0001553878-17-000069 · primary_doc.xml · nonDerivative · entry 4 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,393 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 13, 2017. The 73,415 options exercised and sold by the reporting person were due to expire on December 12, 2017. F4 · price: Sale prices ranged from $131.38 to $132.36. Read SEC document |
| November 22, 2017 Filed Nov 24, 2017 23:55 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 25,036 | $130.88 | $3,276,711.68 |
DisclosureSEC source: 0001553878-17-000069 · primary_doc.xml · nonDerivative · entry 3 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,826 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 13, 2017. The 73,415 options exercised and sold by the reporting person were due to expire on December 12, 2017. F3 · price: Sale prices ranged from $130.38 to $131.37. Read SEC document |
| November 22, 2017 Filed Nov 24, 2017 23:55 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 25,263 | $129.97 | $3,283,432.11 |
DisclosureSEC source: 0001553878-17-000069 · primary_doc.xml · nonDerivative · entry 2 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,862 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 13, 2017. The 73,415 options exercised and sold by the reporting person were due to expire on December 12, 2017. F2 · price: Sale prices ranged from $129.39 to $130.35. Read SEC document |
| November 22, 2017 Filed Nov 24, 2017 23:55 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 73,415 | $31.39 | $2,304,496.85 |
DisclosureSEC source: 0001553878-17-000069 · primary_doc.xml · nonDerivative · entry 1 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,125 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 13, 2017. The 73,415 options exercised and sold by the reporting person were due to expire on December 12, 2017. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 22:35 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (Right to Buy) · Derivative | 74,000 | $0.00 Strike: $31.39 | $0.00 |
DisclosureSEC source: 0001553878-17-000068 · primary_doc.xml · derivative · entry 9 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,415 Underlying: Common Stock · 74,000 shares Expires 2017-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 13, 2017. The 74,000 options exercised and sold by the reporting person were due to expire on December 12, 2017. F9 · derivative.exercise_date: The stock option vested as to 25% of the shares on the first anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. F1 · derivative.expiration_date: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 13, 2017. The 74,000 options exercised and sold by the reporting person were due to expire on December 12, 2017. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 22:35 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 600 | $130.22 | $78,130.80 |
DisclosureSEC source: 0001553878-17-000068 · primary_doc.xml · nonDerivative · entry 7 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,710 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 13, 2017. The 74,000 options exercised and sold by the reporting person were due to expire on December 12, 2017. F7 · price: Sale prices ranged from $130.15 to $130.41. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 22:35 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 4,850 | $129.57 | $628,414.50 |
DisclosureSEC source: 0001553878-17-000068 · primary_doc.xml · nonDerivative · entry 6 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,310 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 13, 2017. The 74,000 options exercised and sold by the reporting person were due to expire on December 12, 2017. F6 · price: Sale prices ranged from $129.11 to $130.00. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 22:35 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 10,571 | $128.48 | $1,358,204.36 |
DisclosureSEC source: 0001553878-17-000068 · primary_doc.xml · nonDerivative · entry 5 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,160 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 13, 2017. The 74,000 options exercised and sold by the reporting person were due to expire on December 12, 2017. F5 · price: Sale prices ranged from $128.09 to $129.08. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 22:35 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 7,120 | $127.54 | $908,084.80 |
DisclosureSEC source: 0001553878-17-000068 · primary_doc.xml · nonDerivative · entry 4 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,731 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 13, 2017. The 74,000 options exercised and sold by the reporting person were due to expire on December 12, 2017. F4 · price: Sale prices ranged from $127.08 to $128.06. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 22:35 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 28,399 | $126.60 | $3,595,398.60 |
DisclosureSEC source: 0001553878-17-000068 · primary_doc.xml · nonDerivative · entry 3 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,851 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 13, 2017. The 74,000 options exercised and sold by the reporting person were due to expire on December 12, 2017. F3 · price: Sale prices ranged from $126.08 to $127.05. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 22:35 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 22,460 | $125.54 | $2,819,718.24 |
DisclosureSEC source: 0001553878-17-000068 · primary_doc.xml · nonDerivative · entry 2 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,250 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 13, 2017. The 74,000 options exercised and sold by the reporting person were due to expire on December 12, 2017. F2 · price: Sale prices ranged from $125.07 to $126.05. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 22:35 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 74,000 | $31.39 | $2,322,860.00 |
DisclosureSEC source: 0001553878-17-000068 · primary_doc.xml · nonDerivative · entry 1 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,710 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 13, 2017. The 74,000 options exercised and sold by the reporting person were due to expire on December 12, 2017. Read SEC document |
| November 06, 2017 Filed Nov 8, 2017 22:25 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantPerformance Stock Option 2015 (right to buy) · Derivative | 16,250 | $0.00 Strike: $88.95 | $0.00 |
DisclosureSEC source: 0001553878-17-000065 · edgardoc.xml · derivative · entry 1 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,250 Underlying: Common Stock · 16,250 shares Expires 2025-12-18 F1 · kind: On December 18, 2015, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option will vest upon the achievement of each of four specific clinical development and regulatory events, as approved by our compensation committee. Effective November 6, 2017, the compensation committee of the Company determined the first performance criterion had been met and the option vested as to one-quarter of the shares. Read SEC document |
| September 20, 2017 Filed Sep 22, 2017 21:08 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantPerformance Stock Option 2013 (right to buy) · Derivative | 25,000 | $0.00 Strike: $63.00 | $0.00 |
DisclosureSEC source: 0001553878-17-000051 · edgardoc.xml · derivative · entry 1 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2023-12-17 F1 · kind: On December 18, 2013, the reporting person was granted a performance based stock option to purchase shares of ALNY Common Stock. One-third of the shares subject to the option will vest upon the achievement of each of three specific clinical development and regulatory events, as approved by our compensation committee. Effective September 20, 2017, the compensation committee of the company determined the second performance criteria had been met and the option will vest as to one-third of the shares. Read SEC document |
| September 14, 2017 Filed Sep 18, 2017 20:09 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionStock Option (right to buy) · Derivative | 18,868 | $0.00 Strike: $2.09 | $0.00 |
DisclosureSEC source: 0001209191-17-053149 · doc4.xml · derivative · entry 4 MARAGANORE JOHN · CIK 0001180432 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: CommonStock · 18,868 shares Expires 2022-01-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option vests in 48 equal monthly installments, commencing on April 1, 2011. Read SEC document |
| September 14, 2017 Filed Sep 18, 2017 20:09 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 600 | $131.82 | $79,090.02 |
DisclosureSEC source: 0001209191-17-053149 · doc4.xml · nonDerivative · entry 3 MARAGANORE JOHN · CIK 0001180432 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,843 F2 · price: The range in prices for the transaction reported on this line was $131.80 to $131.90. The average weighted price was $131.8167. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 14, 2017 Filed Sep 18, 2017 20:09 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 18,268 | $131.19 | $2,396,642.86 |
DisclosureSEC source: 0001209191-17-053149 · doc4.xml · nonDerivative · entry 2 MARAGANORE JOHN · CIK 0001180432 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,443 F1 · price: The range in prices for the transaction reported on this line was $130.80 to $131.75. The average weighted price was $131.1935. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 14, 2017 Filed Sep 18, 2017 20:09 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionCommon Stock | 18,868 | $2.09 | $39,434.12 |
DisclosureSEC source: 0001209191-17-053149 · doc4.xml · nonDerivative · entry 1 MARAGANORE JOHN · CIK 0001180432 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,711 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 24, 2017 Filed Aug 28, 2017 20:17 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionStock Option (right to buy) · Derivative | 13,839 | $0.00 Strike: $2.09 | $0.00 |
DisclosureSEC source: 0001209191-17-050378 · doc4.xml · derivative · entry 5 MARAGANORE JOHN · CIK 0001180432 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,868 Underlying: CommonStock · 13,839 shares Expires 2022-01-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option vests in 48 equal monthly installments, commencing on April 1, 2011. Read SEC document |
| August 24, 2017 Filed Aug 28, 2017 20:17 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 6,385 | $96.32 | $615,019.16 |
DisclosureSEC source: 0001209191-17-050378 · doc4.xml · nonDerivative · entry 3 MARAGANORE JOHN · CIK 0001180432 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,597 F2 · price: The range in prices for the transaction reported on this line was $95.65 to $96.60. The average weighted price was $96.3225. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 24, 2017 Filed Aug 28, 2017 20:17 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 4,700 | $95.13 | $447,088.91 |
DisclosureSEC source: 0001209191-17-050378 · doc4.xml · nonDerivative · entry 2 MARAGANORE JOHN · CIK 0001180432 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,982 F1 · price: The range in prices for the transaction reported on this line was $94.65 to $95.60. The average weighted price was $95.1253. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 24, 2017 Filed Aug 28, 2017 20:17 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionCommon Stock | 13,839 | $2.09 | $28,923.51 |
DisclosureSEC source: 0001209191-17-050378 · doc4.xml · nonDerivative · entry 1 MARAGANORE JOHN · CIK 0001180432 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,682 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 02, 2017 Filed Aug 28, 2017 20:17 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 2,754 | $96.74 | $266,424.99 |
DisclosureSEC source: 0001209191-17-050378 · doc4.xml · nonDerivative · entry 4 MARAGANORE JOHN · CIK 0001180432 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,843 F3 · price: The range in prices for the transaction reported on this line was $96.65 to $96.95. The average weighted price was $96.7411. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 07, 2017 Filed Jul 11, 2017 20:34 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantPerformance Stock Option 2014 (right to buy) · Derivative | 25,000 | $0.00 Strike: $96.45 | $0.00 |
DisclosureSEC source: 0001553878-17-000044 · edgardoc.xml · derivative · entry 1 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 25,000 shares Expires 2024-12-17 F1 · kind: On December 17, 2014, the reporting person was granted a performance based stock option to purchase shares of ALNY Common Stock. One-third of the shares subject to the option will vest upon the achievement of each of three specific clinical development and regulatory events, as approved by our compensation committee. Effective July 7, 2017, the compensation committee of the Company determined the second performance criteria had been met and the option vested as to one-third of the shares. Read SEC document |
| June 13, 2017 Filed Jun 15, 2017 21:05 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock option (right to buy) · Derivative | 8,000 | $0.00 Strike: $50.73 | $0.00 |
DisclosureSEC source: 0001209191-17-040193 · doc4.xml · derivative · entry 1 MARAGANORE JOHN · CIK 0001180432 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common stock · 8,000 shares Expires 2027-06-12 F1 · derivative.exercise_date: This option was granted on June 13, 2017. The shares underlying this option vest as to 100% of the underlying shares on June 13, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.